对蒙塔纳尼等人的评论。使用新型钾结合剂优化心力衰竭和高钾血症患者的肾素-血管紧张素-醛固酮系统抑制剂治疗：快速综述和荟萃分析。2021年，，5483。
Comment on Montagnani et al. Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis. 2021, , 5483.
作者信息
Zarzuela Donna, Chin Alex
机构信息
Global Medical Affairs, AstraZeneca, Gaithersburg, MD 20878, USA.
出版信息
J Clin Med. 2022 May 13;11(10):2755. doi: 10.3390/jcm11102755.
Abstract
The recent rapid review and meta-analysis by Montagnani et al. [...].
摘要
蒙塔尼亚尼等人最近进行的快速综述和荟萃分析[……]。
相似文献
1
Comment on Montagnani et al. Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis. 2021, , 5483.对蒙塔纳尼等人的评论。使用新型钾结合剂优化心力衰竭和高钾血症患者的肾素-血管紧张素-醛固酮系统抑制剂治疗：快速综述和荟萃分析。2021年，，5483。
J Clin Med. 2022 May 13;11(10):2755. doi: 10.3390/jcm11102755.
2
Novel potassium binders to optimize RAASi therapy in heart failure: A systematic review and meta-analysis.新型钾结合剂优化心力衰竭患者肾素-血管紧张素-醛固酮系统抑制剂治疗：一项系统评价和荟萃分析。
Eur J Intern Med. 2024 Jan;119:109-117. doi: 10.1016/j.ejim.2023.08.022. Epub 2023 Aug 28.
3
Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis.心力衰竭合并高钾血症患者使用新型钾结合剂优化肾素-血管紧张素-醛固酮系统抑制剂治疗：快速回顾与荟萃分析
J Clin Med. 2021 Nov 23;10(23):5483. doi: 10.3390/jcm10235483.
4
Management of RAASi-associated hyperkalemia in patients with cardiovascular disease.心血管疾病患者 RAASi 相关高钾血症的管理。
Heart Fail Rev. 2021 Jul;26(4):891-896. doi: 10.1007/s10741-020-10069-3. Epub 2021 Feb 18.
5
Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study).高钾血症与新型钾结合剂的使用：来自挪威韦斯特福尔郡的单中心经验（PotBind研究）
Int J Nephrol Renovasc Dis. 2023 Mar 16;16:73-82. doi: 10.2147/IJNRD.S401623. eCollection 2023.
6
Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure.开发一种健康经济模型，以评估心力衰竭患者最佳血清钾管理的潜在益处。
J Med Econ. 2018 Dec;21(12):1172-1182. doi: 10.1080/13696998.2018.1518239. Epub 2018 Sep 14.
7
Safety and efficacy of new potassium binders on hyperkalemia management in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials.新型钾结合剂在心力衰竭患者高钾血症管理中的安全性和有效性：系统评价和随机对照试验的荟萃分析。
Clin Res Cardiol. 2023 Jul;112(7):991-1002. doi: 10.1007/s00392-023-02215-2. Epub 2023 May 4.
8
The Efficacy and Safety of Patiromer for Heart Failure Patients: A Systematic Review and Meta-Analysis.帕替罗姆用于心力衰竭患者的疗效与安全性：一项系统评价和Meta分析
Cardiovasc Drugs Ther. 2024 Dec;38(6):1245-1257. doi: 10.1007/s10557-023-07473-w. Epub 2023 Jun 7.
9
Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?甾体或非甾体类 MRAs：我们是否仍应通过钾结合剂来启用 RAASi 的使用？
Nephrol Dial Transplant. 2023 May 31;38(6):1355-1365. doi: 10.1093/ndt/gfac284.
10
Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.在英国的一个新诊断的慢性肾脏病或心力衰竭患者队列中，观察到肾素-血管紧张素-醛固酮系统抑制剂剂量、高钾血症与不良临床结局之间的真实世界关联。
J Am Heart Assoc. 2019 Nov 19;8(22):e012655. doi: 10.1161/JAHA.119.012655. Epub 2019 Nov 12.
引用本文的文献
1
The Efficacy and Safety of Patiromer for Heart Failure Patients: A Systematic Review and Meta-Analysis.帕替罗姆用于心力衰竭患者的疗效与安全性：一项系统评价和Meta分析
Cardiovasc Drugs Ther. 2024 Dec;38(6):1245-1257. doi: 10.1007/s10557-023-07473-w. Epub 2023 Jun 7.
本文引用的文献
1
Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis.心力衰竭合并高钾血症患者使用新型钾结合剂优化肾素-血管紧张素-醛固酮系统抑制剂治疗：快速回顾与荟萃分析
J Clin Med. 2021 Nov 23;10(23):5483. doi: 10.3390/jcm10235483.
2
Letter to the editor regarding ''Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia'.致编辑的信：关于“帕替罗姆和环硅酸锆钠治疗高钾血症：一项系统评价和荟萃分析：帕替罗姆和环硅酸锆钠治疗高钾血症”
Curr Ther Res Clin Exp. 2021 Nov 2;95:100651. doi: 10.1016/j.curtheres.2021.100651. eCollection 2021.
3
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.勘误：《2021欧洲心脏病学会（ESC）急性和慢性心力衰竭诊断与治疗指南》：由欧洲心脏病学会（ESC）急性和慢性心力衰竭诊断与治疗工作组制定，并得到了ESC心力衰竭协会（HFA）的特别贡献。
Eur Heart J. 2021 Dec 21;42(48):4901. doi: 10.1093/eurheartj/ehab670.
4
Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis.帕替罗姆和环硅酸锆钠治疗高钾血症：一项系统评价和荟萃分析
Curr Ther Res Clin Exp. 2021 Jul 5;95:100635. doi: 10.1016/j.curtheres.2021.100635. eCollection 2021.
5
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.KDIGO 2021慢性肾脏病血压管理临床实践指南
Kidney Int. 2021 Mar;99(3S):S1-S87. doi: 10.1016/j.kint.2020.11.003.
6
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.《2017年美国心脏病学会（ACC）心力衰竭治疗优化专家共识决策路径2021年更新：关于射血分数降低的心力衰竭的10个关键问题解答：美国心脏病学会解决方案集监督委员会报告》
J Am Coll Cardiol. 2021 Feb 16;77(6):772-810. doi: 10.1016/j.jacc.2020.11.022. Epub 2021 Jan 11.
7
Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.肾脏疾病中的钾离子稳态和血钾紊乱管理：KDIGO 争议会议的结论。
Kidney Int. 2020 Jan;97(1):42-61. doi: 10.1016/j.kint.2019.09.018. Epub 2019 Oct 10.
8
Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE.环硅酸锆钠治疗高钾血症的疗效和安全性：HARMONIZE 的 11 个月开放标签扩展研究。
Am J Nephrol. 2019;50(6):473-480. doi: 10.1159/000504078. Epub 2019 Oct 28.
9
Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.高钾血症患者中使用硅锆酸钠的 12 个月 3 期研究。
Clin J Am Soc Nephrol. 2019 Jun 7;14(6):798-809. doi: 10.2215/CJN.12651018. Epub 2019 May 20.
Zotero 插件